

No.: 21/2025 /CV-MP

Hanoi, June 9 2025

INFORMATION DISCLOSURE

To: - State Securities Commission

- Hanoi Stock Exchange

1. Organization name : **MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY**

- Stock code : MED

- Address: No. 358 Giai Phong Street, Phuong Liet Ward, Thanh Xuan District, Hanoi

- Information disclosure person: Mr. Mai Nhat Thanh

Type of information disclosed: ☒ Periodic ☐ Extraordinary ☐ As required

2. Information disclosure content :

Notice of meeting invitation, Agenda of the 2025 Annual General Meeting of Shareholders

3. This information was published on the company's website on June 9, 2025 at the link:
<http://www.mediplantex.com/vi/thong-tin-co-dong.html>

We hereby commit that the information published above is accurate and are fully legally responsible for the content of the published information./.

**MEDIPLANTEX NATIONAL PHARMACEUTICAL
JOINT STOCK COMPANY
GENERAL DIRECTOR**



Mai Nhat Thanh



MEETING INVITATION NOTICE

THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS

MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

Dear: Shareholders of MediPlantex National Pharmaceutical Joint Stock Company

Pursuant to the Charter on the Organization and Operation of MediPlantex National Pharmaceutical Joint Stock Company and in consideration of the Company's current business conditions, the Board of Directors respectfully announces and cordially invites esteemed shareholders to attend the 2025 Annual General Meeting of Shareholders with the following details:

1. Time: The General Meeting will be convened at 08:30 AM on **Monday, June 30, 2025** (shareholder reception will begin at 08:00 AM on June 30, 2025).

2. Venue: T99 Guest House of the Capital Military Zone – No. 99 Le Duan Street, Cua Nam Ward, Hoan Kiem District, Hanoi.

3. Agenda: The General Meeting shall discuss and approve the following matters:

- Report of the Board of Directors on its performance in 2024 and the proposed operational plan for 2025;
- Report of the Board of Management on the 2024 business and production results and the implementation plan for 2025;
- Report of the Board of Supervisors on its 2024 activities and supervisory work, along with the proposed plan for 2025;
- Approval of the audited financial statements for the year 2024;
- Selection of an independent auditing firm for the 2025 financial statements;
- Approval of the profit distribution plan and dividend payout ratio for 2024, and the proposed profit distribution plan and dividend payout ratio for 2025;
- Approval of remuneration for the Board of Directors and the Board of Supervisors for 2025;
- Approval of the Election of an Additional Member to the Board of Directors for the 2024–2029 Term;
- Other matters within the authority of the General Meeting;

4. Conditions for Participation:

- All shareholders listed in the register of securities holders of MediPlantex National Pharmaceutical Joint Stock Company, as finalized by the Vietnam Securities Depository and Clearing Corporation on May 29, 2025, and individuals duly authorized by such shareholders, are eligible to attend the General Meeting.

- In cases where shareholders (or an authorized representatives) do not present a valid Citizen Identification Card/Personal Identification Card and the original power of attorney (in the case of authorized attendance), they shall not be deemed eligible to participate in the General Meeting.



5. Confirmation of Attendance: To ensure the thorough organization of the General Meeting, shareholders are kindly requested to confirm their direct participation or authorize another individual to attend the Meeting on their behalf. Confirmation should be sent to Mediplantex National Pharmaceutical Joint Stock Company by post, by phone at 024.38643363 / 091.611.7939, or via email at trang.chuh@mediplantex.com no later than 4:30 PM on June 25, 2025.

6. Shareholders or authorized representatives attending the General Meeting are required to bring the following documents:

- ❖ A valid original copy of the Identity Card/Passport/Citizen Identification Card (still within its validity period);
- ❖ The original Power of Attorney (enclosed with this notice), in the case of authorized attendance at the General Meeting.
- ❖ **Note:** Delegates attending the General Meeting are kindly requested to make their own arrangements for transportation, meals, and accommodation before and after the Meeting.

7. General Meeting Documents:

All general meeting documents are fully published and regularly updated on the official website of Mediplantex National Pharmaceutical Joint Stock Company at: <http://www.mediplantex.com/>

8. Other Matters:

To ensure the thorough preparation of the General Meeting, shareholders or groups of shareholders holding at least 5% of the Company's total voting shares who wish to propose additions to the meeting agenda are kindly requested to submit their proposals in writing to the Company no later than 4:30 PM on June 25, 2025.

In the event that shareholders do not receive the Meeting Invitation due to objective reasons, they shall still retain the right to attend the Annual General Meeting of Shareholders. Shareholders who have not received the Meeting Invitation are kindly requested to contact the Company for assistance if necessary.

9. Documents Enclosed with the Meeting Invitation Notice:

- ❖ Registration Form or Power of Attorney for attending the 2025 Annual General Meeting of Shareholders;
- ❖ Agenda of the 2025 Annual General Meeting of Shareholders;

10. For further information regarding the General Meeting, please contact:

MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

No. 358 Giai Phong Street, Thanh Xuan District, Hanoi

Phone: 024.38643363 / 091.611.7939 - Email: trang.chuh@mediplantex.com

Respectfully inviting esteemed shareholders to attend the meeting to ensure the success of the General Meeting.

This notice replaces the official Meeting Invitation.

ON BEHALF OF THE BOARD OF DIRECTORS



Thai Khac Minh





AGENDA OF THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

Time: 8:30 AM, Monday, June 30, 2025.

Venue: T99 Guest House of the Capital Military Zone – No. 99 Le Duan Street, Cua Nam Ward, Hoan Kiem District, Hanoi.

AGENDA Time	Detailed Agenda	Execution
8:00 AM - 8:30 AM	Reception of shareholders and delegates attending the 2025 Annual General Meeting of Shareholders	The Organizing Committee of the General Meeting
	Verification of delegate credentials and distribution of documents	The Delegate Credential Verification Committee
8:30 AM - 9:15 AM	Opening of the meeting and introduction of delegates	The Organizing Committee of the General Meeting
	Report on the verification of shareholder credentials	
	Approval of the General Meeting's agenda	
	Approval of the working regulations and voting at the General Meeting	
	Approval of the Presidium of the General Meeting	
	Approval of the Secretariat and the Vote Counting Committee	
Part 1: 9:15 AM - 10:15 AM Reports & Proposals	- Report of the Board of Directors on its performance in 2024 and the proposed operational plan for 2025.	Representative of the Board of Directors
	- Report of the Board of Management on the 2024 business and production results and the implementation plan for 2025.	Representative of the Board of Management
	- Report of the Board of Supervisors on its 2024 activities and supervisory work, along with the proposed plan for 2025.	Representative of the Board of Supervisors
	- Proposal for the approval of the audited financial statements for 2024;	Representative of the Board of Directors



AGENDA Time	Detailed Agenda	Execution
	- Proposal for the selection of an independent auditing firm for the 2025 financial statements;	Representative of the Board of Supervisors
	- Proposal for the approval of the profit distribution plan and dividend payout ratio for 2024, and the proposed profit distribution plan and dividend payout ratio for 2025;	Representative of the Board of Directors
	- Proposal for the approval of remuneration for the Board of Directors and the Board of Supervisors for 2025;	Representative of the Board of Directors
	- Approval of the Election for the Additional Member of the Board of Directors for the 2024–2029 Term	Representative of the Board of Directors
	- Other matters within the authority of the General Meeting of Shareholders.	Representative of the Board of Directors
10:15 AM - 10:30 AM	Discussion of the reports and proposals	Chairperson of the General Meeting
10:30 AM - 10:45 AM	Conduct voting on the matters submitted to the General Meeting of Shareholders and elect an additional member to the Board of Directors for the 2024–2029 term	
10:45 AM - 11:00 AM	Break	
11:00 AM - 11:10 AM	Announcement of the voting and election results at the General Meeting of Shareholders	Ballot Counting Committee
11:10 AM - 11:20 AM	Presentation of the draft Minutes and Resolutions of the Meeting	Secretary Committee
11:20 AM - 11:30 AM	Approval of the Minutes and Resolutions of the Meeting	Chairperson of the General Meeting
	Conclusion and declaration of the Meeting's closure	



SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

**REGISTRATION FORM FOR ATTENDING OR POWER OF ATTORNEY FOR
ATTENDING THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS**

To: Mediplantex National Pharmaceutical Joint Stock Company

Shareholder's Name:
Legal Representative (for organizations):
Identity Card/Personal Identification Card/Passport/Business Registration No.: issued on at
Address:
Total Number of Shares Represented or Owned: shares
(In words: shares)
(Shareholder should select one of the two options below, marking the appropriate box)

1. REGISTRATION FOR ATTENDANCE ☐

2. POWER OF ATTORNEY FOR ATTENDANCE ☐

Authorized Representative Information:

Name of Individual/Organization: Shareholder Code (if applicable):
Identity Card/Personal Identification Card/Passport/Business Registration No.: issued on at
Address:
Total Number of Shares Represented or Owned: shares
(In words: shares)

Note: In the event that a shareholder is unable to attend and cannot authorize another individual, the shareholder is kindly requested to grant authorization to a member of the Company's Board of Directors from the list provided below:

No.	Full name	Position	Mark selection	Number of authorized shares
01	Tran Xuan Dinh	Member of the BOD		
02	Tran Nguyen Hoang An	Member of the BOD		
03	Nguyen Thi Thuy	Member of the BOD		
04	Thai Khac Minh	Independent Member of the BOD		

(Note: Please mark (X) next to the name of the board member to whom you wish to authorize your voting rights. Shareholders may only authorize one individual for the entirety of their shares. In the case of authorizing multiple individuals, please clearly indicate the number of shares delegated to each member).

Delegated authority details:

- The authorized party shall represent the principal to attend and vote on matters at the 2025 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company, and to exercise all rights and fulfill all obligations at the General Meeting related to the number of shares authorized.
- We take full responsibility for this authorization and hereby commit to strictly comply with the applicable laws and the Charter of Mediplantex National Pharmaceutical Joint Stock Company, with no subsequent claims or complaints.

Note:

- The authorized party is not permitted to delegate the authorized shares, whether owned personally or granted by the principal, to any third party, and must bring their National ID Card/Citizen Identification Card/Passport when attending the meeting.
- If either the principal or the authorized party is an organization, the authorization must bear the signature of the legal representative and the official seal of the organization.
- This power of attorney is only valid if it is the original document and contains the handwritten signatures of both parties. This authorization shall become void upon the conclusion of the 2025 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company.

Shareholder / Principal

(Signature and full name, with seal if applicable)

Dated, 2025

Authorized Representative

(Signature and full name, with seal if applicable)